Published in Cancer Weekly, March 2nd, 2004
The data from the study highlights the utility of Cotara when used in combination with radiofrequency ablation (RFA) in the treatment of hepatic cancer metastases.
Cotara is Peregrine's radiolabeled tumor necrosis therapy (TNT) targeting monoclonal antibody. Cotara has received approval from the U.S. Food and Drug Administration to start a registration clinical trial for brain cancer in the U.S.
Radiolabeled TNT has received marketing approval for the treatment of advanced lung cancer in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.